Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2017

Filing Date
Filed February 16, 2018
Period End
December 31, 2017
Security
IDXX
One revenue dollarkept$0.13
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 16, 2018. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' 2017 10-K shows a company with strong top-line momentum and expanding margins.

Revenue rose 10.9% to $1.97 billiona (organic growth of 10.4%), driven mainly by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 74% of consolidated revenue) grew 13.3%. Income from operations increased 17.9% to $413.0 million, and the operating margin expanded from 19.7% to 21.0%. Diluted EPS rose to $2.94 from $2.44, helped by a roughly $28 million tax benefit from the adoption of ASU 2016-09 and a lower effective tax rate of 30.9%.

The balance sheet remains levered by design. Stockholders' equity is negative at $(53.8) million because of heavy share repurchases ($278 millionb in 2017), and the company carries $1.26 billion of total debt, mostly a $655 million revolver and senior notes. Management reports a gross debt to Adjusted EBITDA ratio of 2.41x and a net debt ratio of 1.51x, well within the 3.5x covenant.

Cash and marketable securities total $472 millionc. Management also plans to liquidate marketable securities in 2018 to pay down the revolver, and it booked a provisional $48.8 million deemed repatriation tax under the Tax Act. Looking forward, management expects the New Revenue Standard (ASC 606) to add roughly $10 million to 2018 revenue, with an estimated retained-earnings charge below $10 million.

The 2018 effective tax rate is guided to 20–21%, and capital expenditures are planned at about $140 milliond. Key risks disclosed include customer consolidation (corporate hospital chains and buying consortiums), competition, sole-source supplier dependence, currency strength in the U.S. dollar (39% of revenue is international), and the expiration of certain patents. The company has never paid a cash dividend.

Key Highlights

  1. Revenue grew 10.9% to $1,969.1 million in 2017 (10.4% organic), with CAG revenue up 11.9% to $1,703.4 million.
  2. CAG recurring diagnostic revenue reached $1,451.7 million (about 74% of consolidated revenue), up 13.3%, led by reference laboratory services (+13.6%) and IDEXX VetLab consumables (+14.9%).
  3. Income from operations rose 17.9% to $413.0 million; operating margin expanded to 21.0% from 19.7%, and gross margin reached 55.7%.
  4. Diluted EPS was $2.94 versus $2.44 in 2016 (+20.5%), aided by about $28 million of tax benefits from share-based payment accounting changes and a 30.9% effective tax rate.
  5. Share repurchases totaled $278 million in 2017 (1.75 million shares in open-market purchases), and about 5.0 million shares remain under the authorization; stockholders' equity is negative at $(53.8) million.
  6. Leverage is moderate: gross debt to Adjusted EBITDA was 2.41x and net debt to Adjusted EBITDA was 1.51x, against a 3.5x covenant. Plans call for liquidating $284 million of marketable securities in 2018 to pay down the $655 million revolver.
  7. Management guides to a 2018 effective tax rate of 20–21% and expects the New Revenue Standard to add roughly $10 million to 2018 revenue.

Follow one dollar

Of each $1.00 of revenue in FY2017, IDEXX Laboratories kept $0.13.

  1. Revenue$1.97B100.0%
  2. Cost of revenue−$871.7M44.3%
  3. Gross profit$1.10B55.7%
  4. Operating costs−$684.4M34.8%
  5. Operating income$413.0M21.0%
  6. Interest, other & tax−$149.9M7.6%
  7. Net income$263.1M13.4%
Computed from 10-KFY2017filed February 16, 2018Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2017 revenue went

$1.97B
  • Cost of revenue: $871.7M, 44% of revenue
  • Other operating costs: $575.2M, 29% of revenue
  • Net income: $263.1M, 13% of revenue
  • R&D: $109.2M, 5.5% of revenue
  • Interest, other & tax: $149.9M, 7.6% of revenue

Kept 13% as net income

Full revenue history →

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$1.97B$1.78B+10.9%
Cost of Revenue$871.68M$799.99M+9.0%
Gross Profit$1.10B$975.44M+12.5%
R&D Expenses$109.18M$101.12M+8.0%
Operating Income$413.03M$350.24M+17.9%
Interest Expense$37.23M$32.05M+16.2%
Net Income$263.14M$222.04M+18.5%
EPS (Basic)$3.00$2.47+21.5%
EPS (Diluted)$2.94$2.44+20.5%
Shares Outstanding (Basic)87.77M89.73M−2.2%
Shares Outstanding (Diluted)89.57M90.88M−1.4%

Frequently Asked Questions

  1. Why is IDEXX's stockholders' equity negative, and is that a concern?

    Equity is negative ($(53.8) million at year-end 2017) because cumulative share repurchases (treasury stock of $1.91 billion) exceed retained earnings and paid-in capital. It is a deliberate capital-return strategy rather than a sign of losses. Retained earnings grew to $803.5 million in 2017. Leverage (net debt to Adjusted EBITDA of 1.51x) is moderate and covenant compliance is comfortable, so the negative equity is largely an accounting outcome of buybacks.

  2. How much of IDEXX's revenue is recurring, and why does it matter?

    About 74% of 2017 consolidated revenue came from recurring diagnostic sales, including IDEXX VetLab consumables, rapid assay kits, and reference lab services. These carry higher gross margins than instrument placements and provide durable, predictable cash flow. The installed base of Catalyst chemistry analyzers reached about 47,000 units, which supports future consumable volume.

  3. What is the impact of the Tax Cuts and Jobs Act on IDEXX?

    The Tax Act lowered the U.S. federal rate to 21% and created a one-time deemed repatriation tax. IDEXX recorded a provisional $48.8 million liability, payable over eight years, and a roughly $17 million reduction in net deferred tax liabilities that boosted Q4 2017 net income. The company expects a 20–21% effective tax rate in 2018, which should lift future earnings, though the repatriation charge is a near-term cash obligation.

  4. What are the main risks to IDEXX's growth?

    Key risks include consolidation among veterinary customers (corporate hospital chains such as Mars/VCA and buying consortiums that can shift purchasing and reference lab volume away from IDEXX), intensifying competition, dependence on sole-source suppliers for many consumables, a stronger U.S. dollar (39% of revenue is international, with about 21% of revenue in USD-sourced products sold abroad), and the expiration of certain patents. The company also faces potential changes in testing patterns from vaccines or disease eradication.

  5. Will the New Revenue Standard (ASC 606) change IDEXX's reported results?

    IDEXX adopts ASC 606 on a modified retrospective basis in Q1 2018. Management expects a net increase of about $10 million in 2018 revenue, with earlier recognition of certain up-front loyalty and volume-commitment instrument placements, offset by deferral of revenue on rebate-based instrument marketing programs and a shift toward higher recurring revenue over time. The transition is expected to produce a retained-earnings charge of under $10 million, and the economics of customer programs are not expected to change.